TRANSFUSION MEDICINE

Transfusion-associated circulatory overload and transfusion-related acute lung injury

John W. Semple,[1-5] Johan Rebetz,[1] and Rick Kapur[1]

[1]Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden; [2]Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Canada; and [3]Department of Pharmacology, [4]Department of Medicine, and [5]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

Transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI) are syndromes of acute respiratory distress that occur within 6 hours of blood transfusion. TACO and TRALI are the leading causes of transfusion-related fatalities, and specific therapies are unavailable. Diagnostically, it remains very challenging to distinguish TACO and TRALI from underlying causes of lung injury and/or fluid overload as well as from each other. TACO is characterized by pulmonary hydrostatic (cardiogenic) edema, whereas TRALI presents as pulmonary permeability edema (non-cardiogenic). The pathophysiology of both syndromes is complex and incompletely understood. A 2-hit model is generally assumed to underlie TACO and TRALI disease pathology, where the first hit represents the clinical condition of the patient and the second hit is conveyed by the transfusion product. In TACO, cardiac or renal impairment and positive fluid balance appear first hits, whereas suboptimal fluid management or other components in the transfused product may enable the second hit. Remarkably, other factors beyond volume play a role in TACO. In TRALI, the first hit can, for example, be represented by inflammation, whereas the second hit is assumed to be caused by antileukocyte antibodies or biological response modifiers (eg, lipids). In this review, we provide an up-to-date overview of TACO and TRALI regarding clinical definitions, diagnostic strategies, pathophysiological mechanisms, and potential therapies. More research is required to better understand TACO and TRALI pathophysiology, and more biomarker studies are warranted. Collectively, this may result in improved diagnostics and development of therapeutic approaches for these life-threatening transfusion reactions. (*Blood*. 2019;133(17):1840-1853)

Historical and current perspective

The occurrence of transfusion-associated circulatory overload (TACO) first received attention in the 1930s. In 1936, Plummer reported 5 fatalities due to circulatory overload after blood transfusion[1] followed by more publications by Pygott[2] and DeGowin[3] in the 1930s, and Drummond[4] and Pelner and Waldman[5] in the 1940s and 1950s. Pulmonary edema was observed in these cases, and patients with left-sided heart disease were found to be at particular risk.[4,5] Despite this early awareness, it was not until the 1990s when TACO received renewed attention and was seen as a distinct clinical entity.[6] Currently, TACO is the most frequent pulmonary complication of transfusion, and it is an independent risk factor for in-hospital morbidity and mortality with increased incidence in a mixed intensive care unit population.[7] The estimated frequency of TACO varies from 1% in hemovigilance reports, up to 8% in postoperative elderly patients, and up to 11% in critically ill patients.[8-10] Using a prospective active surveillance algorithm, the incidence of TACO was found to be 1%.[11] In a pediatric intensive care population consisting of 136 patients, the incidence of TACO was estimated to be between 1.5% and 11%.[12] The National Blood Collection and Utilization Survey report described TACO to occur in 1:14 000 transfused components.[13] TACO appears to be one of the leading causes of transfusion-related fatalities, with 44.1% of the reported transfusion-related fatalities being from TACO (60/136 reported transfusion-related deaths from 2010 to 2017) according to the Serious Hazards of Transfusion (SHOT) report.[14] The Food and Drug Administration (FDA) reported that 30% of the reported transfusion-related fatalities were due to TACO (56/186 reported transfusion-related deaths from 2012 to 2016).[15]

Transfusion-related acute lung injury (TRALI) was first reported in 1951 by Barnard, who described a patient with acute leukemia who died upon blood transfusion due to an acute pulmonary reaction due to a hypersensitivity response.[16] In 1957, Brittingham also described a TRALI case of a severe pulmonary reaction due to transfused blood containing high-titer leukoagglutinins.[17] In 1966, Phillips et al reported 3 transfused patients who suffered from pulmonary edema without fluid overload.[18] In 1970, Ward observed the occurrence of noncardiogenic pulmonary edema possibly due to antileukocyte antibodies,[19] and in 1971, Thompson et al published a case report concerning a fatal pulmonary reaction to HLA-incompatible blood transfusion.[20] It was

Figure 1. Chest radiographs of a TACO and TRALI patient. Patient at time of TACO occurrence (A), and the same patient after resolution of TACO (B). Pretransfusion patient (C), and the same patient at time of TRALI occurrence (D). Normal chest radiographs without signs of pulmonary edema (B-C); infiltrative changes indicative of pulmonary edema (A,D). Adapted from Agnihotri and Agnihotri[110] and Vlaar and Juffermans[22] with permission.

not until 1983 when TRALI was officially recognized as a separate disease entity because it was described to occur due to passive transfer of antileukocyte antibodies.[21] The National Blood Collection and Utilization Survey reported TRALI to occur 1:64 000 transfused components,[13] and the frequency of TRALI has been estimated to be ~0.08% to 15.1% per patient and 0.01% to 1.12% per product.[22] The FDA has reported TRALI to be the leading cause of transfusion-related fatalities for many years with 34% of the reported transfusion-related fatalities being from TRALI (64/186 reported transfusion-related deaths from 2012 to 2016).[15] In contrast, the 2017 SHOT report published that ~4% of the reported transfusion-related fatalities were due to TRALI (5/136 reported transfusion-related deaths from 2010 to 2017).[14] Survival of TRALI in critically ill patients has been reported to be as low as 53% compared with 83% in acute lung injury control patients.[23]

Clinical presentation and diagnosis

TACO and TRALI are life-threatening transfusion reactions, and it remains challenging to accurately diagnose and distinguish both syndromes. Both TACO and TRALI present with the onset of acute respiratory distress (hypoxemia) within 6 hours of a blood transfusion and demonstrate infiltrates on a frontal chest radiograph indicative of the presence of pulmonary edema (Figure 1). Clinical definitions have been established for both syndromes (Table 1). For TACO, this includes the National Healthcare Safety Network definitions published in 2016[24] or the 2011 International Society of Blood Transfusion (ISBT) criteria,[25] whereas for the diagnosis of TRALI, the 2005 National Heart, Lung, and Blood Institute Working Group definitions[26] or the 2004 Canadian Consensus Conference criteria[27] are commonly used (Table 1). The clinical definitions of TACO may include evidence of positive fluid balance or cardiogenic involvement, which may manifest as left heart failure, elevated blood pressure, or tachycardia. In contrast, TRALI is strictly

noncardiogenic, without evidence of left arterial hypertension, and thus, circulatory overload must be excluded. In addition, no temporal relationship to an alternative risk factor for acute lung injury (eg, pneumonia, sepsis, aspiration, multiple trauma, and acute pancreatitis) may be present for the diagnosis of TRALI; otherwise, it has to be classified as "possible TRALI." It has been suggested that the transfusion itself may have a minor contribution in possible TRALI and that this term should therefore be replaced by "transfused acute respiratory distress syndrome (ARDS)."[28,29] Others, however, argue against this by stating that Possible TRALI is a distinct clinical entity, which is especially evident in critically ill and injured patients.[30] Despite the similarity in clinical presentation between TACO and TRALI, key diagnostic features have been identified that may aid in clinical diagnosis and differentiation of TACO vs TRALI (Table 2).[31] Unfortunately, the tools to perform these diagnostic analyses may not be widely available. These key diagnostic features include assessment of hydrostatic pulmonary pressure (increased in TACO), protein levels in edema fluid (protein poor in TACO), response to diuretics (may occur in TACO), and cardiogenic nonlaboratory parameters, which may be impaired in TACO (eg, decreased systolic injection fraction, increased systolic blood pressure, increased vascular pedicle width, and increased cardiothoracic ratio on chest radiograph, in TACO). Increased ventricular filling or myocardial stretching may be assessed as well in the diagnosis of TACO by analyzing the levels of BNP or N-terminal pro-BNP because both have demonstrated a significant positive correlation between pre- and posttransfusion levels in TACO patients.[32,33] Caution, however, is required with the use of natriuretic peptides as a diagnostic measure for distinguishing TACO from TRALI, because these levels may also be significantly increased in critically ill patients suffering from TRALI.[34] Importantly, cardiac ischemia (ischemic changes on electrocardiography or increased new troponin T levels) must be excluded in diagnosing TACO. Supportive

Table 1. Clinical definitions for TACO and TRALI

NHSN 2016-TACO definition[24]	ISBT 2011-TACO definition[25]	NHLBI Working Group 2005-TRALI definition[26]	Canadian Consensus Conference 2004-TRALI definition[27]
New onset or exacerbation of ≥3 of the following within 6 h of transfusion: (a) Acute respiratory distress (dyspnea, orthopnea, and cough) (b) Evidence of positive fluid balance (c) Elevated brain natriuretic peptide (d) Radiographic evidence pulmonary edema (e) Evidence of left heart failure (f) Elevated central venous pressure	Any 4 of the following occurring within 6 h of completion of transfusion: (a) Acute respiratory distress (b) Tachycardia (c) Elevated blood pressure (d) Acute or worsening pulmonary edema of frontal chest radiograph (e) Evidence of positive fluid balance	Patients without acute lung injury (ALI) risk factor(s) other than transfusion: In patients with no ALI immediately before transfusion, a temporal association of transfusion and ALI is made if there is: (a) New ALI,[96] and (b) The onset of symptoms or signs is during or within 6 h after the end of transfusion of 1 or more plasma-containing blood products As there is no other ALI risk factor, the new ALI is inferred to be mechanistically related to transfusion (ie, TRALI) Patients with ALI risk factor(s) other than transfusion: In patients with no ALI immediately before transfusion, a temporal association of transfusion and ALI is made if there is: (a) New ALI,[96] and (b) The onset of symptoms or signs is during or within 6 h after the end of transfusion of 1 or more plasma-containing blood products By assessing the patient's clinical course, the new ALI is either: (a) TRALI, and the new ALI is inferred to be mechanistically related to the transfusion, or both the transfusion and the alternative risk factor, or (b) Not TRALI, and the new ALI is mechanistically related to the alternative ALI risk factor alone, whereas the transfusion is coincidental	ALI: (a) Acute onset (b) Hypoxemia: PaO$_2$/FiO$_2$ ≤ 300, or SpO$_2$ < 90% on room air (or other clinical evidence of hypoxemia in a nonresearch setting) (c) Bilateral infiltrates on frontal chest radiograph (d) No evidence of left atrial hypertension (ie, circulatory overload) No preexisting ALI before transfusion During or within 6 h of transfusion No temporal relationship to an alternative risk factor for ALI If clear temporal relationship to an alternative risk factor for ALI (in combination with previous listed criteria), then defined as "possible TRALI"

NHLBI, National Heart, Lung and Blood Institute; NHSN, National Healthcare Safety Network.

clinical and laboratory features may perhaps further help in the diagnosis of TACO or TRALI (Table 3).[35] This includes physical examination of neck veins (distended in TACO), auscultation (rales, S3 in TACO), and blood pressure measurement (increased in TACO). Regarding body temperature, TRALI patients are frequently febrile, but fever may be present in one-third of TACO patients as well.[36] Supportive laboratory investigations may include determination of white blood cell counts (transient leukopenia and mild thrombocytopenia in TRALI),[37-40] the detection of antibodies against recipient HLA class I/II and/or human neutrophil antigen (HNA) antigens in the involved blood donor (in ~80% of TRALI cases),[41] and analysis of cytokines, as is discussed later in more detail. It remains, however, unknown if blood cell counts are affected and if antileukocyte antibodies could be present in TACO patients. Notably, there are ongoing international efforts to further define TACO, which include the 2017 ISBT working party on Haemovigilance together with the International Haemovigilance Network, which

have proposed revised TACO criteria to establish a surveillance definition for reporting and tracking purposes.[42]

Pathophysiology

Two-hit model

The pathogeneses of TACO and TRALI are incompletely understood. As a general pathophysiological framework, a 2-hit model has been suggested for both TACO[7] and TRALI.[43,44] The first hit represents the underlying, preexisting clinical condition of the patient (transfusion-recipient risk factors), whereas the second hit is conveyed by the transfused blood product. Both hits are required for development of TACO or TRALI. The first hit in TACO may be represented by the poor adaptability for volume overload. A recent large prospective study enrolling 200 patients with TACO identified congestive heart failure, cardiomegaly on chest radiograph, pretransfusion diuretic use,

Table 2. Key diagnostic features differentiating TACO from TRALI

Key diagnostic feature	Specific diagnostic readout	TACO	TRALI
Acute onset of respiratory distress symptoms	Onset <6 h upon blood transfusion	Yes	Yes
Hypoxemia	SpO_2 < 90% or PaO_2/FiO_2 < 300 mm Hg on room air	Yes	Yes
Pulmonary edema	Bilateral infiltrates on chest radiograph	Yes	Yes
Alternative risk factors for ALI	eg, pneumonia, sepsis, aspiration, multiple trauma, acute pancreatitis	No	No
			Yes: possible TRALI
Hydrostatic pulmonary pressure increased	Pulmonary artery occlusion pressure >18 mm Hg	Yes	No
Protein-poor edema fluid	Edema or plasma protein concentration <0.65 at the onset of acute respiratory failure	Yes	No
Increased ventricular filling/myocardial stretching[32-34]	B-type natriuretic peptide (BNP) >250 or pre-/posttransfusion BNP ratio >1.5 or N-terminal pro-BNP >1000 pg/mL	Yes	Yes*/No
Response to diuretics	Rapid and significant improvement	Yes	No
Cardiogenic nonlaboratory evidence for circulatory overload	Systolic ejection fraction <45 and no severe valvular heart disease on echocardiography	Yes	No
	Systolic blood pressure >160		
	Vascular pedicle width >65 mm and cardiothoracic ratio >0.55 on chest radiograph		
Cardiac ischemia	New ischemic changes on electrocardiography or new troponin T levels of >0.05	No	No

Modified from Gajic et al.[31]

*In transfused critically ill patients.

elevated blood pressure, acute kidney injury, chronic kidney disease, plasma transfusion, and emergency surgery to be risk factors associated with TACO.[45] Also, a recent retrospective cohort study of 66 TACO patients found cardiac failure, renal failure, and the degree of positive fluid balance as risk factors for TACO development.[46] Previously, congestive heart failure and renal dysfunction were identified as common features in TACO in a retrospective study of 98 TACO patients, which, in addition, also identified an age of over 70 years as a risk factor for TACO development.[47] Advanced age was also shown to increase the incidence of TACO in perioperative noncardiac surgery patients.[48] The second hit in TACO may be reflected by suboptimal fluid management and inappropriate infusion practices (such as rapid infusion rates), which have frequently been related to the onset of TACO.[47] In a perioperative setting of noncardiac surgery, the incidence of TACO was found to be increased with the volume transfused and the total intraoperative fluid balance.[48] Remarkably, it was recently observed that the degree of positive fluid balance appeared to be associated less with the development of TACO than with the development of circulatory overload in the absence of transfusion.[46] This lower association of positive fluid balance with the development of TACO may be due to the increase in colloid-osmotic pressure due to the transfusion product stimulating fluids from the extravascular space into the intravascular space in an attempt to contribute a more effective circulating volume. Alternatively, it may indicate that other factors in the transfused blood product besides the transfusion volume could play a role in

the onset of TACO. Combined with the first hit, these factors may possibly contribute to inflammation in the transfused recipient resulting in TACO, as will be discussed later.

In TRALI, first-hit risk factors include chronic alcohol abuse, shock, liver surgery, current smoking, higher peak airway pressure while undergoing mechanical ventilation, positive intravascular fluid balance,[49] low interleukin-10 (IL-10) levels,[50-53] and systemic inflammation.[53] Systemic inflammation may be reflected in the plasma cytokine profiles (increased IL-6 and IL-8 levels as discussed later) but also via increased levels of C-reactive protein (CRP). CRP is an acute-phase protein that rapidly increases during acute infections and inflammation and is widely used in clinic as an inflammatory biomarker.[54] CRP was shown to be elevated in TRALI patients[55] and functionally enabled the first hit in the development of TRALI in a murine model by increasing the levels of the neutrophil (PMN)-chemoattractant macrophage inflammatory protein (MIP)-2 (murine homolog of IL-8), resulting in increased pulmonary PMN accumulation.[56] The second hit in TRALI may be conveyed by antileukocyte antibodies or other factors present in the transfusion product. In ~80% of cases, anti-HLA class I or II or anti-HNA antibodies are implicated to be involved in triggering TRALI,[41] although this may be even higher depending on the detection methods used.[57] In the remaining 20% of TRALI cases, non–antibody factors/biological response modifiers are suggested to contribute the second hit, and these may possibly include lipid mediators, extracellular vesicles, and aged blood cells (as described in "Non-antibody–mediated TRALI").[58]

Table 3. Supportive clinical and laboratory features further differentiating TACO from TRALI

Supportive clinical and laboratory features	TACO	TRALI
Neck veins	Distended	Normal
Auscultation	Rales, S3	Rales, No S3
Blood pressure	Hypertension	Hypotension
Body temperature	Fever may be present (1/3 of patients)[36]	Febrile
White blood cell count	Unknown	Transient leukopenia (infrequent) and mild thrombocytopenia[37-40]
Leukocyte antibodies	Unknown	May be present (±80%)[41]: Anti-HLA class I antibodies Anti-HLA class II antibodies Anti-HNA antibodies
Posttransfusion cytokines[49-51,59]	IL-6 increased IL-8 not increased IL-10 increased No changes in TNF-α, GM-CSF	IL-6 increased IL-8 increased IL-10 not increased No changes in TNF-α, GM-CSF

Modified from Skeate et al.[35]

Cytokine profiles

Cytokine profiles may shed light on the pathophysiologic environment of TACO and TRALI; however, in TACO, this has rarely been investigated. A nested case control study involving 29 TACO patients, 147 control patients, as well as 70 TRALI patients has initiated these important investigations.[50] In this study, the proinflammatory cytokine IL-6 was found to be significantly elevated in posttransfusion TACO patients compared with matched controls. Levels of the proinflammatory cytokine IL-8, on the other hand, were not elevated in pre- or posttransfusion TACO patients, whereas in TRALI patients, both IL-6 and IL-8 levels were elevated pre- as well as posttransfusion in the same study.[50] Furthermore, the anti-inflammatory cytokine IL-10 was found to be increased in both pre- and posttransfusion TACO patients, whereas IL-10 levels remained low in pre- and posttransfusion TRALI patients.[50] No changes were found in pre- or posttransfusion TACO or TRALI patients regarding granulocyte macrophage-colony stimulating factor (GM-CSF) or tumor necrosis factor-α (TNF-α).[50] Other studies examining cytokine levels in TRALI have reported increased levels of pre- and posttransfusion IL-6 and IL-8 in cardiac surgery patients,[59] increased levels of pretransfusion IL-8,[49] and low/nonelevated levels of posttransfusion IL-10.[51] One study, however, found IL-10 levels to be increased in TRALI patients.[60] This may be due to the fact that this study investigated fold changes of paired samples prior to and following transfusion, in contrast to the comparison of posttransfusion TRALI samples vs transfused

controls.[50,51] The posttransfusion cytokine levels in TACO and TRALI based on these studies are summarized in Table 3. The data so far appear promising, especially considering that they may facilitate the challenging distinction between TACO and TRALI (in a symptomatic setting posttransfusion). Low IL-8 levels in combination with elevated IL-10 levels may potentially help support a diagnosis of TACO, whereas increased IL-8 levels in combination with low IL-10 levels may potentially aid in the diagnosis of TRALI. It will be very important, however, to validate these cytokine profiles in larger patient cohorts of TRALI and especially TACO.

Pathophysiological mechanisms

TACO Research into the pathophysiology of TACO has been surprisingly limited over the years.[7] The pathophysiology of TACO was initially thought to be identical to the well-studied mechanisms of congestive heart failure or pulmonary hydrostatic edema, but is now recognized to be more complex. It remains unknown which pathways are involved in generating the pulmonary hydrostatic edema (protein-poor edema fluid) in TACO. Recently, studies have started to investigate risk factors for development of TACO and, as previously discussed, cardiac failure, renal failure, and positive fluid balance are first-hit components responsible for the poor adaptability for volume overload. Second hits may be suboptimal fluid management or other components present in the transfusion product. Secretion of IL-10, which was found to be increased in TACO patients,[50] is known to require specific stimulation such as by microbial products or specific antibodies.[52,61] It is therefore possible that factors in the transfused blood product could perhaps be mediating this effect. Regarding IL-10 levels in TACO, however, an important role for the recipient's status (comorbidities or postoperative status) must be considered as well. IL-10 levels were also found to be increased in pretransfusion TACO patients, although apparently to a lower extent than in posttransfusion TACO patients.[50] Furthermore, 1 study found that the occurrence of TACO decreased ~50% by the introduction of universal leukoreduced products,[62] indicating that other factors besides volume overload may be involved. As this was only a single retrospective study, further validation in animal models, in prospective clinical trials, and via hemovigilance systems is required to investigate whether TACO rates indeed decrease due to leukoreduction. Similarly, it has been observed that in perioperative noncardiac patients, the rates of TACO incidence decreased from 2004 to 2011,[48] which may be related to the exclusion of female plasma donors for transfusions in this period. Alternatively, it may be well possible that this decrease in TACO incidence could also have been related to changes in clinical practice (such as declines in transfusion related to patient blood management). Other factors that could potentially be involved may be related to inflammation or cytokine levels. The proinflammatory cytokine IL-6 was found to be increased in TACO patients,[50] and fever was described to occur in one-third of the patients developing TACO.[36] It will be important to further research the contribution of the transfusion product beyond the volume alone, including the role of inflammation. Because of lack of experimental animal models for TACO, almost nothing is known about the cellular moieties involved in the pathophysiology of TACO. One paper reported the presence of intra-alveolar neutrophils (without the formation of neutrophil extracellular traps [NETs]) in the lungs of a TACO patient,[63] which

TACO

TRALI

First hits (in recipient)
- Poor adaptability for volume overload
  - Cardiac failure
  - Renal failure
  - Positive fluid balance

First hits (in recipient)
- Inflammation
- Increased IL-8
- Chronic alcohol abuse
- Older age
- Acute renal failure
- Trauma
- Liver surgery
- Mechanical ventilation
- Increased CRP
- Low IL-10

Low IL-10

Hydrostatic edema (cardiogenic)

Permeability edema (noncardiogenic)

Increased fluid filtration due to increased hydrostatic pressure

Inflammation?

Cellular players?

IL-8

Increased EC permeability

Post-transfusion cytokines
IL-6 increased
IL-8 not increased
IL-10 increased
No changes TNF-α, GM-CSF

Post-transfusion cytokines
IL-6 increased
IL-8 increased
IL-10 not increased
No changes TNF-α, GM-CSF

Second hits (in transfusion product)
- Suboptimal fluid management
- Other factors in transfusion product?

Second hits (in transfusion product)
- Anti-HLA class I/II antibodies
- Anti-HNA antibodies
- Non-antibody mediators

RK

|			
Anti-HLA class I antibody	Red blood cell-microparticles	NET	
Anti-HLA class II antibody	Platelet	sCD40L	
Anti-HNA antibody	Platelet-microparticles	C5a	
PMN	Lyso-PC	Gastrointestinal microbiota	
Monocyte	Platelet VEGF	CRP	
Macrophage	Lipid/acid sphingomyelinase from stored platelets	Protein	
CD4+CD25+FoxP3+ Treg	Lipid from stored red blood cells	ROS	
Dendritic cell	Inflamed/damaged endothelial cell	Fluid-filled alveoli	
Red blood cell	Intact endothelial cell		

Figure 2. Pathophysiological mechanisms of TACO and TRALI in the lungs. Pathways A-N are systematically discussed in the main text. sCD40L, soluble CD40 ligand; VEGF, vascular endothelial growth factor. This figure was in part created with images adapted from Servier Medical Art by Servier, which is licensed under a Creative Commons Attribution 3.0 Unported License.

additionally supports the involvement of an inflammatory component in TACO. The current knowledge regarding the pathophysiology of TACO is depicted in Figure 2.

TRALI Although much more is known regarding the pathophysiology of TRALI as compared with TACO, it remains complex and still incompletely understood. TRALI results in

Table 4. Overview of evidence for and against the involvement of specific cell types in the pathogenesis of TRALI, based on both TRALI animal models and/or human data

Cell type	Supporting evidence for involvement in TRALI	Evidence against involvement in TRALI	Overall effect in TRALI
PMNs	• PMNs are observed in TRALI lungs upon autopsy[86,87] • In vitro TRALI models have shown PMN-induced endothelial cell damage. Antibody-mediated second hits: anti-HNA-3a antibody,[74] anti-HLA antibody,[70] low IgM serum.[97] Non-antibody–mediated second hits: lyso-PC,[98] soluble CD40 ligand,[85] platelet microparticles[82] • NETs detected in plasma (n = 14) and lungs of TRALI patients and in murine plasma and lung microcirculation of mice undergoing anti-MHC class I antibody–mediated TRALI (upon LPS priming)[63] Suggested mechanism: Platelets induce NET formation and NETs induce lung injury via direct toxicity to pulmonary endothelial cells • NET biomarkers found in serum of TRALI patients (n = 5) and in murine lung alveoli using an anti-MHC class I antibody–mediated TRALI model (upon LPS priming)[73] Suggested mechanism: NETs formed through direct priming of PMNs by anti-HNA-3a antibodies[73] • PMNs were shown to interact with von Willebrand factor via CTL-2, enabling anti-HNA-3a to signal via CD11b/CD18, resulting in PMN-activation and agglutination[99] • Pulmonary PMN infiltration has frequently been observed in multiple animal models of TRALI, both antibody mediated[52,56,63,66,68,75,76,99-103] and non-antibody mediated[103,104] • PMN-FcγRs were found to be essential in a murine anti-MHC class I antibody–mediated TRALI model (without LPS priming)[66] Suggested mechanism: Anti-MHC class I antibody binds to the pulmonary endothelium and sequesters PMNs via their FcγRs, resulting in PMN activation and TRALI induction[66] • PMN depletion fully prevented TRALI occurrence using murine anti-MHC class I antibody–mediated TRALI models (without LPS priming)[52,66,100] • PMN and ROS are critically required for TRALI induction in a murine model of anti-MHC class I antibody–mediated TRALI (model based on CD4$^+$ T-cell depletion and without LPS, using C57BL/6 gp91phox knock-out mice)[52] • In a 2-event in vivo rat TRALI model, inflammatory priming PMNs induced MHC class II surface expression and pulmonary endothelium activation. Anti-MHC class II antibodies subsequently targeted sequestered PMNs resulting in TRALI[71]	• TRALI reported in a neutropenic patient[105] • No alveolar PMN influx observed upon lung tissue histology analysis of 2 TRALI patients[106] • Occurrence of TRALI after PMN depletion in a murine anti-HNA-3a TRALI model (despite a decreased disease severity)[75] • No dependence on PMNs (and partial independence of FcγRs) but on complement component C5a in a murine anti-MHC class I antibody–mediated TRALI model[67]	Pathogenic
Monocytes and/or macrophages	• Anti-MHC class I antibody–mediated murine (SCID mice, without LPS priming) TRALI induction was completely abrogated upon monocyte depletion (and restored upon repletion with purified monocytes)[68] Suggested mechanism: Anti-MHC class I antibody binding to monocytes induces the secretion of the PMN-chemoattractant MIP-2 (murine homolog of IL-8), resulting in pulmonary PMN recruitment and TRALI[68] • Depletion or inactivation of monocytes/macrophages in vivo fully suppressed TRALI in murine model of anti-MHC class I antibody–mediated TRALI (without LPS priming)[67] Suggested mechanism: Anti-MHC class I antibody binding to endothelial cells activates complement with production of C5a, which then binds to the C5aR on monocytes/macrophages, attracting these cells to the lungs and inducing them to produce ROS, damaging the endothelium and inducing TRALI[67] • Anti-HLA class II antibodies induce monocyte activation in an ex vivo rodent model of TRALI, which subsequently results in activation of PMNs, which then damage the pulmonary endothelium[72]		Pathogenic

SEMPLE et al

Table 4. (continued)

Cell type	Supporting evidence for involvement in TRALI	Evidence against involvement in TRALI	Overall effect in TRALI
	• TRALI monocytes were activated in vitro by sera implicated in TRALI, resulting in increased production of TNF-α, IL-1β, and Tissue Factor over a 4-h period compared with control sera[107]		
Platelets	• Occurrence of thrombocytopenia in TRALI patients[37-40] • Reported thrombocytopenia in murine anti-MHC class I antibody–mediated TRALI model based on CRP infusion[56] • Platelet depletion (platelet depleting antibody injected 4 h prior to TRALI induction) protected mice from TRALI in a murine anti-MHC class I–mediated TRALI model (with LPS priming)[100] Suggested mechanism: Platelets induce NET formation (which induce lung injury via direct toxicity to pulmonary endothelial cells) and targeting platelet activation with aspirin or a glycoprotein IIb/IIIa inhibitor decreased NET formation and TRALI[63] • Stored platelet-derived vascular endothelial growth factor potentially mediates increased lung vascular permeability in isolated-perfused rat lungs[79] • Plasma and lipids from stored platelets enable TRALI in an LPS-primed rat model[78] • Lyso-PC from stored platelets causes pulmonary and systemic coagulopathy in an LPS-primed rat model, via PMN-priming in vitro[81] • Platelet-derived microparticles enable PMN-mediated pulmonary endothelial cell damage in vitro[82] • Aged platelets induce lung injury via acid sphingomyelinase in an LPS-primed murine TRALI model[80]	• No thrombocytopenia detected in murine model of anti-MHC class I antibody–mediated TRALI (without LPS priming)[66] • No effect of inducing thrombocytopenia or of pharmacological and genetic targeting of platelet functions, on the development of TRALI in a murine anti-MHC class I antibody–mediated TRALI model (with LPS priming)[108] • Platelet depletion (with platelet depleting antibody injected 24 and 48 h prior to TRALI induction or by injection of neuraminidase) did not suppress TRALI development in a murine model of anti-MHC class I–mediated TRALI (without LPS priming)[67]	Pathogenic? Dispensable?
Red blood cells	• Plasma and lipids from red blood cells and leukoreduced red blood cells primed PMNs and induced ALI in rat model with LPS priming[84] • Red blood cell–derived microparticles may prime PMNs and enable TRALI in LPS-primed mice[83] • Lipids and supernatants from stored red blood cells activate pulmonary endothelium through the BLT2 receptor and protein kinase C activation, and predispose to ALI[77] • Transfusion of supernatant of aged red blood cells induced lung inflammation and coagulopathy in LPS-primed rats[109] • Injection of anti–red blood cell antibody 1 d before induction of anti-MHC class I antibody–mediated murine TRALI resulted in total suppression of TRALI development in BALB/c mice[67]	• Transfusion of 35-d stored autologous red blood cells in LPS-primed human volunteers (with confirmed sepsis/endotoxemia) did not result in lung injury[89]	Pathogenic
CD4$^+$CD25$^+$FoxP3 Tregs and dendritic cells	• Depletion of CD4$^+$CD25$^+$FoxP3$^+$ Tregs or of CD11c$^+$ dendritic cells resulted in low IL-10 levels, which enabled anti-MHC class I antibody–mediated murine TRALI (protection against anti-MHC class I antibody–mediated TRALI was associated with increased IL-10 levels)[52] Suggested mechanism: Depletion of CD4$^+$CD25$^+$FoxP3$^+$ Tregs or of CD11c$^+$ dendritic cells in mice results in low IL-10 levels, which enables increased anti-MHC class I antibody–mediated plasma MIP-2 levels (murine homolog of IL-8), pulmonary PMN infiltration, ROS production, and TRALI development with impaired lung function[52]		Protective
CD8$^+$ T cells		Depletion of CD8$^+$ T cells did not significantly result in the onset of anti-MHC class I antibody–mediated murine TRALI[52]	No significant involvement
B cells		Depletion of B cells did not significantly result in the onset of anti-MHC class I antibody–mediated murine TRALI[52]	No significant involvement

noncardiogenic permeability edema (protein-rich edema fluid). Most of the data on the TRALI pathophysiological mechanisms are derived from animal models or from in vitro cultures of human lung endothelial cells. Animal models of TRALI have significantly facilitated research into the TRALI pathophysiology,[64] but controversies have arisen. The complexity comes from the use of various animal models, various triggers (different types of antibodies or biological response modifiers), and different experimental conditions. When assessing cellular involvement in the pathophysiology of TRALI, which is summarized in Table 4, it appears that PMNs are the key pathogenic cells that mediate lung damage in TRALI,[65] whereas CD4+CD25+FoxP3+ T-regulatory (Treg) cells and dendritic cells appear to be the key protective cells.[52] Furthermore, it seems that monocytes and/or macrophages and red blood cells convey a pathogenic role in TRALI (Table 4). As further described in Table 4, the role of platelets appears pathogenic in TRALI; however, reports have also strongly argued against this pathogenic involvement. Similarly, CD8+ T lymphocytes and B lymphocytes do not appear to have a significant role in the pathophysiology of TRALI (Table 4). Suggested TRALI pathophysiologic mechanisms also depend on the type of antibodies (anti-HLA class I, anti-HLA class II, or anti-HNA antibodies) or biological response modifiers (such as lipids from stored platelets or red blood cells) involved.

Antibody-mediated TRALI Antibody-mediated mechanisms of TRALI are depicted in pathways A-L (Figure 2), and non-antibody–mediated mechanisms are illustrated in pathways M and N of Figure 2. Using an anti–major histocompatibility complex (MHC) class I antibody–mediated murine model, it was suggested that the anti-MHC class I antibody binds to the pulmonary endothelium and sequesters PMNs via their FcγRs, resulting in PMN activation.[66] Subsequently, it has been described that platelets may induce NET formation, causing the NETs to induce direct toxicity to the pulmonary endothelium enabling TRALI[63] (Figure 2 pathway A). Another mechanism may be that anti-MHC class I antibodies may bind the pulmonary endothelial cells activating the complement cascade, resulting in the production of C5a.[67] C5a may then bind to the C5a receptor on monocytes/macrophages, attracting these cells to the lungs and inducing them to produce reactive oxygen species (ROS), which then damages the pulmonary endothelium, resulting in TRALI[67] (Figure 2 pathway B). Importantly, ROS was shown to be critically required for anti-MHC class I antibody–meditated murine TRALI as was demonstrated using gp91phox knock-out mice.[52] Anti-MHC class I antibodies may also target monocytes, inducing secretion of MIP-2, resulting in pulmonary PMN recruitment and TRALI.[68] CRP together with anti-MHC class I antibody can also cause a synergistic increase in both MIP-2 levels and pulmonary PMN accumulation, enabling TRALI.[56] CRP may also directly target the endothelium,[69] and CRP has been described to be elevated in TRALI patients[55] (Figure 2 pathway C). Anti-HLA-A2 antibodies were also shown to activate PMNs and induce endothelial cell damage in vitro[70] (Figure 2 pathway D). Inflammatory priming was shown to induce MHC class II surface expression on PMNs and activation of the pulmonary endothelium, enabling anti-MHC class II antibodies to directly target sequestered PMNs inducing TRALI in a rat model[71] (Figure 2 pathway E). Furthermore, anti-HLA class II antibodies were shown to induce monocyte activation in an ex vivo rodent TRALI model, which subsequently resulted in PMN activation that then damaged the pulmonary endothelium causing TRALI[72]

(Figure 2 pathway F). Anti–HNA-3a antibodies were shown to directly prime PMNs, resulting in the formation of NETs[73] (Figure 2 pathway G) as well as to cause PMN priming enabling PMN-mediated pulmonary endothelial cell damage in vitro[74] (Figure 2 pathway H). Alternatively, anti–HNA-3a antibodies have been shown to directly target lung endothelium cells, causing barrier dysfunction, although the presence of PMNs did aggravate this endothelial barrier dysfunction[75] (Figure 2 pathway I). Using an anti-MHC class I–mediated murine TRALI model, CD4+CD25+ FoxP3+ Tregs and dendritic cells were found to be key protecting cells in TRALI via upregulation of IL-10.[52] This was demonstrated by in vivo Treg and dendritic cell depletions, which corresponded to low IL-10 levels and subsequently enabled anti-MHC class I antibody–mediated TRALI. In addition, this was verified by using IL-10 knock-out mice, which were shown to be hypersensitive to anti-MHC class I antibody–mediated murine TRALI induction[52] (Figure 2 pathway J). Red blood cells may also be pathogenic in antibody-mediated TRALI because RBC depletion with injection with an anti-RBC antibody prevented the onset of anti-MHC class I antibody–mediated TRALI in BALB/c mice[67] (Figure 2 pathway K). The gastrointestinal microbiota was also shown to contribute to the development of antibody-mediated murine TRALI.[76] Mice housed in a more sterile environment (specific pathogen-free mice) were shown to be resistant to anti-MHC class I–mediated TRALI, whereas less sterile housed mice (barrier-free mice) were sensitive to anti-MHC class I antibody–mediated TRALI but become resistant to TRALI upon gut flora depletion using broad-spectrum antibiotics.[76] Interestingly, fecal transplants from TRALI-susceptible mice into the sterile-housed TRALI-resistant mice were able to restore the TRALI responses.[76] The exact interplay between the gastrointestinal flora and TRALI induction mechanisms will need to be further investigated (Figure 2 pathway L).

Non-antibody–mediated TRALI Non-antibody–mediated mechanisms of TRALI may include direct targeting of biological response modifiers toward the pulmonary endothelium. Lipids from stored red blood cells may activate the pulmonary endothelium via the BLT2 receptor and protein kinase C predisposing to acute lung injury.[77] In addition, plasma and lipids from stored platelets may enable TRALI in an lipopolysaccharide (LPS)-primed rat model,[78] and stored platelet-derived vascular endothelial growth factor may also potentially increase lung vascular permeability in rat lungs.[79] Acid sphingomyelinase from aged platelets has also been shown to induce TRALI in LPS-primed mice[80] (Figure 2 pathway M). Biological response modifiers may also mediate TRALI via PMNs, such as lyso-PC, from stored platelets, which may cause pulmonary and systemic coagulopathy in LPS-primed mice in vitro via PMN priming.[81] Furthermore, both platelet- and red blood cell microparticles have been demonstrated to prime PMNs and mediate TRALI in human pulmonary microvascular endothelial cells in vitro and in mice, respectively.[82,83] In addition, lipids from red blood cells were shown to prime PMNs and induce acute lung injury in LPS-primed mice.[84] Soluble CD40 ligand (sCD40L) has been demonstrated to accumulate in stored blood components and enabled PMN-mediated endothelial cell damage in vitro[85] (Figure 2 pathway N). Notably, regarding the role of PMNs in the 2-hit TRALI models, these cells may differentially accumulate in the lungs at various stages between the first and second hits of TRALI induction (Figure 2 pathway C, E, J, or N).

Figure 3. Potential TRALI therapies. Summary of potential therapeutic targets in TRALI. IVIg, IV immunoglobulin. This figure was in part created with images adapted from Servier Medical Art by Servier, which is licensed under a Creative Commons Attribution 3.0 Unported License.

Implications for human TRALI disease The data supporting these mechanisms in human cases of TRALI are limited. Supporting data that are derived from TRALI patients directly include the discussed plasma cytokine profiles (see previous section), increased levels of CRP,[55] detection of NETs in plasma and lungs of TRALI patients,[63] presence of NET biomarkers in serum of TRALI patients,[73] and the observation of PMNs in TRALI lungs upon autopsy.[86,87] Notably, the suggested mechanisms of non-antibody–mediated TRALI have not been confirmed to occur in human studies.[88,89]

Potential therapies and future directions

Unfortunately, for both TACO and TRALI, only supportive measures are available, and specific therapies are lacking. Supportive measures for TACO may include diuresis, oxygen, and intubation. For TRALI, supportive measures may include oxygen, intubation, and judicious fluid and pressor management to maintain hemodynamics. Preventive strategies for TRALI (TRALI mitigation) include donor deferral based on antibody screening (anti-HNA and anti-HLA antibodies), donor deferral based on history of pregnancy or history of transfusion, and deferral of all female donors (use of male-only plasma donors).[90] These TRALI mitigation strategies have been successful in significantly reducing the incidence of TRALI. There was a reduction in plasma-induced TRALI cases in at-risk patient populations (surgery, intensive care unit) and a decreased tendency of plasma-induced TRALI cases in a general patient population.[90] In addition, the FDA reported 35 TRALI cases in 2006, and upon TRALI mitigation, this was reduced to 8 cases in 2016.[15] The SHOT report also described a strong decline from 24 cases in 2003 that dropped to 3 cases in 2017 after introduction of TRALI mitigation strategies.[14] Furthermore, using prospective, active

surveillance, Toy et al observed a TRALI incidence of 2.57 (95% confidence interval, 1.72-3.86) in 2006 vs 0.81 (95% confidence interval, 0.44-1.49) in 2009 per 10 000 transfused units ($P = .002$).[49] Similarly, the incidence of TACO in perioperative noncardiac surgery patients was observed to be 5.5% (119/2162) in 2004 vs 3.0% (57/1908) in 2011 ($P < .001$).[48] In the same patient population, however, the incidence of TRALI/possible TRALI was 1.3% (23/1613) in 2004 vs 1.4% (22/1562) in 2011 ($P = .72$), indicating that no decline in the incidence of TRALI/possible TRALI occurred despite the introduction of TRALI mitigation strategies.[91] The French Haemovigilance Network did also not observe a significant reduction in the overall incidence of TRALI cases between 2007 and 2013.[92] It may be possible, however, that the inclusion of possible TRALI cases together with TRALI cases in these studies could have obscured a decline in true TRALI cases due to the mitigation measures. Limitations of the TRALI mitigation strategies include a shortage of male AB plasma[93] and no decrease in red blood cell and platelet transfusion-related TRALI.[94] Furthermore, no significant effect on 30-day TRALI mortality was observed with low-risk TRALI donor strategies in plasma-induced TRALI cases.[90] It is therefore important to pursue the identification of potential therapies for TRALI.

Recently, potential therapies for TRALI have been reviewed,[53] and it was concluded that the most promising therapeutic strategies to explore are IL-10 therapy, downregulation of CRP levels, targeting ROS, or blocking IL-8 receptors, all focused on the transfusion recipient.[53] More validation and confirmation will be required first for other therapies focused on the transfusion recipient or for therapeutic interventions aimed at the blood transfusion product.[53] IL-10 therapy was shown to not only prophylactically but also therapeutically (ie, after onset of TRALI symptoms) prevent and rescue TRALI in a murine model.[52] Because

IL-10 levels are not elevated in posttransfusion TRALI patients,[50,51] IL-10 therapy may be particularly interesting to explore as a potential therapy. IL-10 administration to healthy volunteers has been shown to be safe and well tolerated.[95] Caution, however, is strongly advised because IL-10 administration may impair the host resistance to infectious pathogens in critically ill patients. We have summarized the potential TRALI therapies in Figure 3.

Regarding potential therapies for TACO, much more patho-physiological knowledge will need to be required first, and development of animal models will be important. It will be imperative to investigate if patients at risk for TACO could be better identified pretransfusion by improving the screening for occult cardiac insufficiency (eg, using echocardiography or measurement of N-terminal pro-BNP). In addition, the effect of reducing the rate and volume of transfusions should be researched in patients at risk for TACO development.

Overall, TACO and TRALI remain significant clinical problems. Further research into the pathophysiological mechanisms will be critical for improvement of diagnostic approaches and for the design and assessment of potential therapeutic strategies. It will be important to expand on biomarker investigations and to validate risk factors for TRALI and TACO. The development of TACO animal models is highly warranted to dissect the disease pathology because other factors besides volume appear to play a significant role in TACO. These approaches may significantly contribute in combating these life-threatening complications of blood transfusion.

Authorship

Contribution: J.W.S. wrote and edited the manuscript; J.R. edited the manuscript; and R.K. wrote and edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for R.K. is Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

ORCID profiles: J.W.S., 0000-0002-1510-0077; R.K., 0000-0002-1608-876X.

Correspondence: John W. Semple Lund University, BMC C14, Klinikgatan 26, 221 84 Lund, Sweden; e-mail: john_w.semple@med.lu.se; and Rick Kapur, Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands; e-mail: r.kapur@sanquin.nl.

REFERENCES

1. Plummer NS. Blood transfusion: a report of six fatalities. *BMJ*. 1936;2(3962):1186-1189.

2. Pygott F. Death after blood transfusion. *BMJ*. 1937;1(3974):496-497.

3. DeGowin EL. Grave sequelae of blood transfusion; a clinical study of 13 cases occurring in 3500 blood transfusions. *Ann Intern Med*. 1938;11(10):1777-1791.

4. Drummond R. Transfusion reactions and fatalities due to circulatory overloading. *BMJ*. 1943;2(4314):319-322.

5. Pelner L, Waldman S. Circulatory overloading during and following blood transfusion; a method of prevention using packed red cells and injection of morphine and atropine. *Am J Cardiol*. 1958;2(4):489-495.

6. Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. *Immunohematology*. 1996;12(2):87-89.

7. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload (TACO): Time to shed light on the pathophysiology. *ISBT Sci Ser*. 2018;*ISBT Sci Ser*. 2019;14(1): 136-139.

8. Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. *Vox Sang*. 2004;87(s2 Suppl 2):62-65.

9. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. *J Bone Joint Surg Am*. 1999;81(1):2-10.

10. Rana R, Fernández-Pérez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. *Transfusion*. 2006; 46(9):1478-1483.

11. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm. *Vox Sang*. 2017;112(1):56-63.

12. De Cloedt L, Emeriaud G, Lefebvre É, et al. Transfusion-associated circulatory overload in a pediatric intensive care unit: different incidences with different diagnostic criteria. *Transfusion*. 2018;58(4):1037-1044.

13. The 2011 National Blood Collection and Utilization Survey Report. https://www.hhs.gov/sites/default/files/ash/bloodsafety/2011-nbcus.pdf. Accessed 1 October 2018.

14. Annual Serious Hazards of Transfusion (SHOT) report 2017. https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Report-2017-WEB-Final-v4-25-9-18.pdf. Accessed 1 October 2018.

15. Fatalities Reported to Food and Drug Administration (FDA) Following Blood Collection and Transfusion; Annual summary for fiscal year 2016. https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf. Accessed 1 October 2018.

16. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. *N Y State J Med*. 1951; 51(20):2399-2402.

17. Brittingham TE. Immunologic studies on leukocytes. *Vox Sang*. 1957;2(4):242-248.

18. Philipps E, Fleischner FG. Pulmonary edema in the course of a blood transfusion without overloading the circulation. *Dis Chest*. 1966;50(6):619-623.

19. Ward HN. Pulmonary infiltrates associated with leukoagglutinin transfusion reactions. *Ann Intern Med*. 1970;73(5):689-694.

20. Thompson JS, Severson CD, Parmely MJ, Marmorstein BL, Simmons A. Pulmonary "hypersensitivity" reactions induced by transfusion of non-HL-A leukoagglutinins. *N Engl J Med*. 1971;284(20): 1120-1125.

21. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. *Am Rev Respir Dis*. 1983;128(1): 185-189.

22. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. *Lancet*. 2013;382(9896):984-994.

23. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related

acute lung injury in the critically ill: a nested case-control study. *Crit Care Med*. 2010; 38(3):771-778.

24. Adapted from Division of Healthcare Quality Promotion; Centers for Disease Control and Prevention. The National Healthcare Safety Network Manual: Biovigilance Component 2016. www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf. Accessed 1 October 2018.

25. The Transfusion-associated Circulatory Overload Definition (2011 revision) by the International Society of Blood Transfusion Working Party on Haemovigilance in collaboration with The International Haemovigilance Network. www.isbtweb.org/fileadmin/user_upload/Proposed_definitions_2011_surveillance_non_infectious_adverse_reactions_haemovigilance_incl_TRALI_correction_2013.pdf. Accessed 1 October 2018.

26. Toy P, Popovsky MA, Abraham E, et al; National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. *Crit Care Med*. 2005;33(4):721-726.

27. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion*. 2004;44(12): 1774-1789.

28. Toy P, Bacchetti P, Grimes B, et al. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. *Transfusion*. 2015;55(5):947-952.

29. Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. *Transfusion*. 2017;57(3): 709-713.

30. Juffermans NP, Vlaar AP. Possible TRALI is a real entity. *Transfusion*. 2017;57(10): 2539-2541.

31. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. *Crit Care Med*. 2006;34(5 suppl): S109-S113.

32. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. *Transfusion*. 2005;45(7):1056-1063.

33. Tobian AA, Sokoll LJ, Tisch DJ, Ness PM, Shan H. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. *Transfusion*. 2008;48(6):1143-1150.

34. Li G, Daniels CE, Kojicic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. *Transfusion*. 2009;49(1):13-20.

35. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. *Curr Opin Hematol*. 2007;14(6):682-687.

36. Parmar N, Pendergrast J, Lieberman L, Lin Y, Callum J, Cserti-Gazdewich C. The association of fever with transfusion-associated circulatory overload. *Vox Sang*. 2017;112(1):70-78.

37. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. *Chest*. 2004;126(1):249-258.

38. Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. *Lancet*. 1984;1(8371):244-246.

39. Ausley MB Jr. Fatal transfusion reactions caused by donor antibodies to recipient leukocytes. *Am J Forensic Med Pathol*. 1987; 8(4):287-290.

40. Leger R, Palm S, Wulf H, Vosberg A, Neppert J. Transfusion-related lung injury with leukopenic reaction caused by fresh frozen plasma containing anti-NB1. *Anesthesiology*. 1999;91(5):1529-1532.

41. Peters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. *Br J Haematol*. 2015;170(5):597-614.

42. International Society of Blood Transfusion Working Party on Haemovigilance in collaboration with the International Haemovigilance Netwerk. Transfusion-associated circulatory overload (TACO): Draft revised reporting criteria April 2017. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwi62KDO-_fgAhVPalAKHWB5CN0QFjAAegQICRA-C&url=http%3A%2F%2Fwww.isbtweb.org%2Ffileadmin%2Fuser_upload%2FTACO_reporting_criteria_April_2017_draft_for_validation.docx&usg=AOvVaw0YRk8-pHAtmN58LxeDQ9AEe. Accessed 1 October 2018.

43. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. *Transfusion*. 1997;37(7):719-726.

44. Silliman CC. The two-event model of transfusion-related acute lung injury. *Crit Care Med*. 2006;34(5 Suppl):S124-S131.

45. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Contemporary risk factors and outcomes of transfusion-associated circulatory overload. *Crit Care Med*. 2018;46(4):577-585.

46. Bosboom JJ, Klanderman RB, Zijp M, et al. Incidence, risk factors, and outcome of transfusion-associated circulatory overload in a mixed intensive care unit population: a nested case-control study. *Transfusion*. 2018;58(2):498-506.

47. Lieberman L, Maskens C, Cserti-Gazdewich C, et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. *Transfus Med Rev*. 2013; 27(4):206-212.

48. Clifford L, Jia Q, Yadav H, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. *Anesthesiology*. 2015;122(1): 21-28.

49. Toy P, Gajic O, Bacchetti P, et al; TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. *Blood*. 2012; 119(7):1757-1767.

50. Roubinian NH, Looney MR, Kor DJ, et al; TRALI Study Group. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions. *Transfusion*. 2015; 55(8):1838-1846.

51. Kapur R, Kim M, Rebetz J, Rondina MT, Porcelijn L, Semple JW. Low levels of interleukin-10 in patients with transfusion-related acute lung injury. *Ann Transl Med*. 2017;5(16):339.

52. Kapur R, Kim M, Aslam R, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. *Blood*. 2017;129(18):2557-2569.

53. Semple JW, McVey MJ, Kim M, Rebetz J, Kuebler WM, Kapur R. Targeting transfusion-related acute lung injury: the journey from basic science to novel therapies. *Crit Care Med*. 2018;46(5):e452-e458.

54. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest*. 2003; 111(12):1805-1812.

55. Kapur R, Kim M, Rondina MT, Porcelijn L, Semple JW. Elevation of C-reactive protein levels in patients with transfusion-related acute lung injury. *Oncotarget*. 2016;7(47): 78048-78054.

56. Kapur R, Kim M, Shanmugabhavananthan S, Liu J, Li Y, Semple JW. C-reactive protein enhances murine antibody-mediated transfusion-related acute lung injury. *Blood*. 2015;126(25):2747-2751.

57. van Stein D, Beckers EA, Peters AL, et al. Underdiagnosing of antibody-mediated transfusion-related acute lung injury: evaluation of cellular-based versus bead-based techniques. *Vox Sang*. 2016;111(1):71-78.

58. Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. *Blood Rev*. 2015; 29(1):51-61.

59. Vlaar AP, Hofstra JJ, Determann RM, et al. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control study. *Crit Care Med*. 2012;40(10):2813-2820.

60. Looney MR, Roubinian N, Gajic O, et al; Transfusion-Related Acute Lung Injury Study Group. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury*. *Crit Care Med*. 2014;42(7): 1676-1687.

61. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. *Nat Rev Immunol*. 2010;10(3):170-181.

62. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. *Transfusion*. 2010;50(12):2738-2744.

63. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular

traps in transfusion-related acute lung injury. *J Clin Invest.* 2012;122(7):2661-2671.

64. Fung YL, Tung JP. How different animal models help us understand TRALI. *ISBT Sci Ser.* 2018;13(3):197-205.

65. Rebetz J, Semple JW, Kapur R. The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion-related acute lung injury. *Transfus Med Hemother.* 2018;45(5):290-298.

66. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. *J Clin Invest.* 2006;116(6):1615-1623.

67. Strait RT, Hicks W, Barasa N, et al. MHC class I-specific antibody binding to non-hematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. *J Exp Med.* 2011;208(12):2525-2544.

68. McKenzie CG, Kim M, Singh TK, Milev Y, Freedman J, Semple JW. Peripheral blood monocyte-derived chemokine blockade prevents murine transfusion-related acute lung injury (TRALI). *Blood.* 2014;123(22):3496-3503.

69. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation.* 2000;102(18):2165-2168.

70. Khoy K, Nguyen MVC, Masson D, Bardy B, Drouet C, Paclet MH. Transfusion-related acute lung injury: critical neutrophil activation by anti-HLA-A2 antibodies for endothelial permeability. *Transfusion.* 2017;57(7):1699-1708.

71. Kelher MR, Banerjee A, Gamboni F, Anderson C, Silliman CC. Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model. *Transfusion.* 2016;56(12):3004-3011.

72. Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. *Blood.* 2011;117(2):669-677.

73. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. *Blood.* 2012;119(26):6335-6343.

74. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. *Blood.* 2007;109(4):1752-1755.

75. Bayat B, Tjahjono Y, Sydykov A, et al. Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells. *Arterioscler Thromb Vasc Biol.* 2013;33(11):2538-2548.

76. Kapur R, Kim M, Rebetz J, et al. Gastrointestinal microbiota contributes to the development of murine transfusion-

77. Silliman CC, Kelher MR, Khan SY, et al. Supernatants and lipids from stored red blood cells activate pulmonary microvascular endothelium through the BLT2 receptor and protein kinase C activation. *Transfusion.* 2017;57(11):2690-2700.

78. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. *Transfusion.* 2003;43(5):633-640.

79. Maloney JP, Ambruso DR, Voelkel NF, Silliman CC. Platelet vascular endothelial growth factor is a potential mediator of transfusion-related acute lung injury. *J Pulm Respir Med.* 2014;4(06):4.

80. McVey MJ, Kim M, Tabuchi A, et al. Acid sphingomyelinase mediates murine acute lung injury following transfusion of aged platelets. *Am J Physiol Lung Cell Mol Physiol.* 2017;312(5):L625-L637.

81. Vlaar AP, Hofstra JJ, Kulik W, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. *Blood.* 2010;116(8):1360-1368.

82. Xie RF, Hu P, Wang ZC, et al. Platelet-derived microparticles induce polymorphonuclear leukocyte-mediated damage of human pulmonary microvascular endothelial cells. *Transfusion.* 2015;55(5):1051-1057.

83. Xie R, Yang Y, Zhu Y, et al. Microparticles in red cell concentrates prime polymorphonuclear neutrophils and cause acute lung injury in a two-event mouse model. *Int Immunopharmacol.* 2018;55:98-104.

84. Silliman CC, Moore EE, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. *Transfusion.* 2011;51(12):2549-2554.

85. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. *Blood.* 2006;108(7):2455-2462.

86. Dry SM, Bechard KM, Milford EL, Churchill WH, Benjamin RJ. The pathology of transfusion-related acute lung injury. *Am J Clin Pathol.* 1999;112(2):216-221.

87. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. *Blood.* 2005;105(6):2266-2273.

88. Peters AL, Vervaart MA, van Bruggen R, et al. Non-polar lipids accumulate during storage of transfusion products and do not contribute to the onset of transfusion-related acute lung injury. *Vox Sang.* 2017;112(1):25-32.

89. Peters AL, van Hezel ME, Cortjens B, et al. Transfusion of 35-day stored RBCs in the presence of endotoxemia does not result in lung injury in humans. *Crit Care Med.* 2016;44(6):e412-e419.

90. Müller MC, van Stein D, Binnekade JM, van Rhenen DJ, Vlaar AP. Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset

of transfusion-related acute lung injury: a meta-analysis. *Transfusion.* 2015;55(1):164-175.

91. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of post-operative transfusion-related acute lung injury. *Anesthesiology.* 2015;122(1):12-20.

92. Andreu G, Boudjedir K, Muller JY, et al. Analysis of transfusion-related acute lung injury and possible transfusion-related acute lung injury reported to the french hemovigilance network from 2007 to 2013. *Transfus Med Rev.* 2018;32(1):16-27.

93. Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. *Transfusion.* 2013;53(7):1442-1449.

94. Arinsburg SA, Skerrett DL, Karp JK, et al. Conversion to low transfusion-related acute lung injury (TRALI)-risk plasma significantly reduces TRALI. *Transfusion.* 2012;52(5):946-952.

95. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol.* 2001;19(1):683-765.

96. Bernard GR, Artigas A, Brigham KL, et al; Consensus Committee. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *J Crit Care.* 1994;9(1):72-81.

97. Nishimura M, Takanashi M, Okazaki H, Satake M. Lung microvascular endothelial cell injury caused by treatment with polymorphonuclear neutrophils and low-IgM serum: a model of transfusion-related acute lung injury. *Hai.* 2006;184(1):25-32.

98. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. *Am J Physiol Cell Physiol.* 2002;283(6):C1592-C1603.

99. Bayat B, Tjahjono Y, Berghöfer H, et al. Choline transporter-like protein-2: new von Willebrand factor-binding partner involved in antibody-mediated neutrophil activation and transfusion-related acute lung injury. *Arterioscler Thromb Vasc Biol.* 2015;35(7):1616-1622.

100. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. *J Clin Invest.* 2009;119(11):3450-3461.

101. Fung YL, Kim M, Tabuchi A, et al. Recipient T lymphocytes modulate the severity of antibody-mediated transfusion-related acute lung injury. *Blood.* 2010;116(16):3073-3079.

102. Semple JW, Kim M, Hou J, et al. Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production. *PLoS One.* 2012;7(2):e31357.

103. Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. *Blood*. 2009;113(9):2079-2087.

104. Tung JP, Fung YL, Nataatmadja M, et al. A novel in vivo ovine model of transfusion-related acute lung injury (TRALI). *Vox Sang*. 2011;100(2):219-230.

105. Finlayson J, Grey D, Kavanagh L, Witt C. Transfusion-related acute lung injury in a neutropenic patient. *Intern Med J*. 2011; 41(8):638-641.

106. Danielson C, Benjamin RJ, Mangano MM, Mills CJ, Waxman DA. Pulmonary pathology of rapidly fatal transfusion-related acute lung injury reveals minimal evidence of diffuse alveolar damage or alveolar granulocyte infiltration. *Transfusion*. 2008;48(11): 2401-2408.

107. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. *Transfusion*. 2003;43(2): 177-184.

108. Hechler B, Maître B, Magnenat S, et al. Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. *J Thromb Haemost*. 2016; 14(6):1255-1267.

109. Vlaar AP, Hofstra JJ, Levi M, et al. Supernatant of aged erythrocytes causes lung inflammation and coagulopathy in a "two-hit" in vivo syngeneic transfusion model. *Anesthesiology*. 2010;113(1):92-103.

110. Agnihotri N, Agnihotri A. Transfusion associated circulatory overload. *Indian J Crit Care Med*. 2014;18(6):396-398.